Physician profile
Ethan Pace Walker
NPI 1124551809
$1,873.55
in general payments reported to CMS, 2019-2025
29 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $427 · 2023: $1,295 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,446.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $321.77 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $232.37 | 2022-2023 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $203.84 | 2022-2023 | |
| Lilly USA, LLC | $167.03 | 2022-2023 | Jardiance, Emgality, Mounjaro |
| Corium, LLC | $147.99 | 2022-2023 | Azstarys |
| Exact Sciences Corporation | $78.28 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $73.42 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $60.70 | 2022-2023 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.52 | 2022-2023 | Xifaxan |
| Axsome Therapeutics, INC. | $52.31 | 2023 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.59 | 2022-2023 | Spiriva Respimat, Jardiance |
| Sumitomo Pharma America, INC. | $44.58 | 2023 | Gemtesa |
| Dexcom, INC. | $43.36 | 2023-2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $39.41 | 2022-2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $34.00 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $33.75 | 2023 | |
| Amgen INC. | $29.40 | 2022 | |
| Merck Sharp & Dohme LLC | $25.49 | 2022-2023 | Verquvo, Steglatro, Belsomra |
| Astellas Pharma US INC | $23.77 | 2023 | Myrbetriq |
| Insulet Corporation | $21.52 | 2023 | Omnipod |
| Xeris Pharmaceuticals, INC. | $19.92 | 2022 | |
| Almatica Pharma LLC | $16.70 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.64 | 2022 | |
| Hologic Sales and Service, LLC | $15.43 | 2022 | |
| Ironshore Pharmaceuticals INC. | $15.28 | 2022 | |
| Ironwood Pharmaceuticals, INC | $15.06 | 2022 | |
| Mylan Specialty L.P. | $14.85 | 2023 | Yupelri |
| Sanofi-Aventis U.S. LLC | $14.53 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $13.04 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ethan Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.